Loading
A phase 1/2 trial of Spevatamig, Paclitaxel / nab-paclitaxel, Gemcitabine in pancreatic ductal adenocarcinoma, run by Phanes Therapeutics, now recruiting.
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) is a phase 1/2 interventional study registered as NCT05482893 by Phanes Therapeutics, with 258 participants planned, started 2023-03-15 and due to reach its primary completion in 2027-12. Interventions recorded: Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab). Conditions listed: Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Phanes Therapeutics, Paclitaxel / nab-paclitaxel, Gemcitabine, Metastatic pancreatic ductal adenocarcinoma.
Shares Phanes Therapeutics, Pancreatic ductal adenocarcinoma.
Shares CAPOX (capecitabine, oxaliplatin), Paclitaxel / nab-paclitaxel, Gemcitabine, Metastatic pancreatic ductal adenocarcinoma.
Shares CAPOX (capecitabine, oxaliplatin), FOLFOX (5-FU, leucovorin, oxaliplatin), Pancreatic ductal adenocarcinoma.
Shares CAPOX (capecitabine, oxaliplatin), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares CAPOX (capecitabine, oxaliplatin), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/